Guggenheim raised the firm’s price target on Guardant Health (GH) to $67 from $56 and keeps a Buy rating on the shares after the company hosted its investor day and updated its long range plan through 2028. Key announcements include the upcoming launch of Shield MCD capabilities in October, the Q4 launch of Reveal Response Monitoring, and the announcement of the in-development Reveal Ultra tissue-informed MRD test, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $70 from $65 at Mizuho
- Guardant Health’s Strong Growth Trajectory and Unique Oncology Approach Earns Buy Rating
- Wolfe upgrades Guardant to Outperform after ‘solid’ analyst day
- Guardant Health price target raised to $70 from $60 at JPMorgan
- Guardant Health upgraded to Outperform from Peer Perform at Wolfe Research